

**Client**  
**Gurugram**  
Pathkind Diagnostics Pvt. Ltd.  
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

**Processed By**  
**Pathkind Diagnostics Pvt. Ltd.**  
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

<b>Name</b> : Mrs. CL108	<b>Billing Date</b> : 07/07/2023 12:17:39
<b>Age</b> : 35 Yrs	<b>Sample Collected on</b> : 10/07/2023 10:01:31
<b>Sex</b> : Female	<b>Sample Received on</b> : 10/07/2023 11:02:13
<b>P. ID No.</b> : P1000100012590	<b>Report Released on</b> : 20/07/2023 18:03:49
<b>Accession No</b> : 10002304646	<b>Barcode No.</b> : 10002304646-01
<b>Referring Doctor</b> : Self	
<b>Referred By</b> :	<b>Ref no.</b> :

**Report Status - Final**

Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**BIOCHEMISTRY****ROMA (Ovarian Malignancy Risk Algorithm)**

Method: CMIA

**CA 125**

Sample: Serum

Method: ECLIA

**49.0 H**

&lt; 35

U/mL

**# Human Epididymis Protein-4 (HE4)**

Sample: Serum

Method: CMIA

31.5

Pre-menopause: <60.5  
Post menopause: <104 Note:  
Ref. Range Changed

pmol/L

**# Roma Value**

Sample: Serum

2.8

&lt;= 7.4

%

**Human Epididymis Protein-4 (HE4)**

Interpretation :

HE4-Human epididymis protein 4.serum

- HE4 assay is to be used as an aid in monitoring response to therapy for patients with invasive epithelial ovarian cancer, in conjunction with clinical findings and other methods of monitoring.
- A change in HE4 level of > or = 25% is considered significant.
- Elevated HE4 levels are associated with ovarian cancer but are not disease-specific. It can falsely rise in healthy women, hypertension, congestive heart failure, benign gynecological diseases.
- HE4 is not recommended for monitoring of patients with known mucinous or germ cell ovarian cancer.

**ROMA (Ovarian Malignancy Risk Algorithm)**

Interpretation :

CA-125 (Cancer Antigen-125).serum

- CA-125 as a screening test was initiated by the fact that about 83% of patients with non-mucinous epithelial ovarian cancers have elevated levels.

10002304646 Mrs. CL108



**Client**  
**Gurugram**  
Pathkind Diagnostics Pvt. Ltd.  
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

**Processed By**  
**Pathkind Diagnostics Pvt. Ltd.**  
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

<b>Name</b> : Mrs. CL108	<b>Billing Date</b> : 07/07/2023 12:17:39
<b>Age</b> : 35 Yrs	<b>Sample Collected on</b> : 10/07/2023 10:01:31
<b>Sex</b> : Female	<b>Sample Received on</b> : 10/07/2023 11:02:13
<b>P. ID No.</b> : P1000100012590	<b>Report Released on</b> : 20/07/2023 18:03:49
<b>Accession No</b> : 10002304646	<b>Barcode No.</b> : 10002304646-01
<b>Referring Doctor</b> : Self	
<b>Referred By</b> :	<b>Ref no.</b> :

### Report Status - Final

Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

2. However, CA-125 has a low specificity & positive predictive value as it can be elevated in other cancers involving pancreas, breast, bladder, lung, liver & in benign conditions like diverticulitis, endometriosis, pelvic tuberculosis, pleural effusion.
3. For therapeutic monitoring serial estimation of CA-125 is recommended.

#### HE4-Human epididymis protein 4, serum

1. HE4 assay is to be used as an aid in monitoring response to therapy for patients with invasive epithelial ovarian cancer, in conjunction with clinical findings and other methods of monitoring.
2. A change in HE4 level of > or = 25% is considered significant.
3. Elevated HE4 levels are associated with ovarian cancer but are not disease-specific. It can falsely rise in healthy women, hypertension, congestive heart failure, benign gynecological diseases.
4. HE4 is not recommended for monitoring of patients with known mucinous or germ cell ovarian cancer.

#### ROMA VALUE

1. Risk stratification of harboring epithelial ovarian cancer can be obtained in pre- and post-menopausal women presenting with adnexal mass using ROMA value (Risk of Ovarian Malignancy Algorithm) calculated from CA-125 & HE4 levels.
2. The sensitivity for stratifying patients with epithelial ovarian cancer into high risk group is 94% and the specificity is 75%.

**Remark :** The ovarian cancer risk calculator accepts values in the following approved ranges only, CA-125 (1-1000 U/ml) and HE4(20-1500 pmol/L). Risk calculation not possible if values are outside these ranges, clinical correlation suggested.

Abbreviation :

CMIA : Chemiluminescence Microparticle Immunoassay

\*\* End of Report\*\*



**Dr. Aarti Khanna Nagpal**

DNB (Pathology)  
Senior Consultant

10002304646 Mrs. CL108

